08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Corticotropin-releasing factor receptor 1 (CRHR1; CRFR1)

Neurology INDICATION: Anxiety In vitro and mouse studies identified a CRHR1 antagonist that could help treat anxiety. Chemical synthesis and in vitro testing of benzimidazole analogs identified a compound that bound CRHR1 with a Ki...
08:00 , Dec 4, 2014 |  BC Innovations  |  Cover Story

GPCRs' grand plans

In a move to expand tenfold the number of known 3D structures of the highly druggable class of GPCRs, Amgen Inc. , Ono Pharmaceutical Co. Ltd. and Sanofi have teamed up with three academic organizations...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Aquaporin-4 (AQP4); corticotropin-releasing factor 1 (CRF1); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) Rat studies suggest inhibiting CRFR1 signaling could help prevent hypoxia-induced cerebral edema,...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
07:00 , Aug 22, 2013 |  BC Innovations  |  Cover Story

Deep pockets

The B class of GPCRs is brimming with therapeutic targets, but thus far, development of small molecule drugs has been stymied. New studies reporting the first-ever crystal structures of members of the family could change...
07:00 , Aug 22, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Crystal structure of corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) bound to a small molecule antagonist A crystal structure of an antagonist-bound...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Clinical News

Xerecept corticorelin: Phase I/II data

Data from 14 evaluable pediatric patients in an open-label, U.S. Phase I/II trial showed that twice-daily subcutaneous Xerecept reduced daily dexamethasone dosing requirements by >50% in 10 patients, 5 of which were able to completely...
08:00 , Jan 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Autism spectrum disorder (ASD) m-Opioid receptor (OPRM1; MOR); corticotropin-releasing factor receptor 1 (CRHR1; CRFR1) Studies in mice suggest antagonizing OPRM1 and/or...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Clinical News

Xerecept corticorelin: Phase I/II data

Data from 15 pediatric patients in the dose-escalation Phase I portion of an open-label, U.S. Phase I/II trial showed that Xerecept led to "substantial" reductions in daily dexamethasone dosing requirements in all patients, with about...
07:00 , Mar 17, 2011 |  BC Innovations  |  Targets & Mechanisms

The hormone trigger in PTSD

Post-traumatic stress disorder is thought to involve changes in the circuitry of brain regions related to fear, although the specific molecular players have been elusive. Now, U.S. researchers have evidence that dysregulation of a brain...